SANTA CLARA, Calif., and SAN FRANCISCO, Oct. 4, 2010
Agilent Technologies Inc. (NYSE: A) and Strand Scientific Intelligence Inc. today announced an agreement to expand the scope of the Agilent GeneSpring bioinformatics system across multiple life-science disciplines; drive future innovation; and deliver new channels for accessing the software and customer support.
Financial details were not disclosed for the multi-year agreement.
"We intend to lead the way in providing tools for integrated biology research, and partnering with Strand is an excellent way of addressing the all-important bioinformatics part of the equation," said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. "Studies combining multiple 'omics experiments are finally delivering the results that were hoped for years ago from systems biology and true translational research, and this is one example of what Agilent is doing to fuel future breakthroughs in biomedical research."
"We've enjoyed a close working relationship with Agilent over the past three years developing GeneSpring for gene expression and Mass Profiler Professional for metabolomics and proteomics," said Francois Mandeville, Strand executive vice president. "We're extremely pleased to take this partnership up to the next level. Developing new scientific intelligence solutions that enable scientists to integrate, model and visualize biological information is an important part of this new agreement, and we also look forward to going beyond this, developing new ways to deliver, customize and support these solutions."
The first tool scheduled to emerge from this partnership will be a version of GeneSpring designed to help users perform statistical analyses of and visualize data from genomics, metabolomics and proteomics together for the first time, using a familiar interface. The partnership also will leverage Strand's technology to enable integrated Next Generation Sequencing (NGS) analysis capabilities for GeneSpring users.
The agreement also includes development of a fully integrated portal for licensing, upgrading and supporting the GeneSpring family of bioinformatics systems.
"We're developing a new transactional model designed to deliver the precise solutions and personalized support that researchers want and need, quickly and easily," Mandeville added.
Agilent and Strand have been working together since August 2007. Strand was developing Stratagene's ArrayAssist software when Agilent acquired Strategene in 2007. After the acquisition, Agilent's GeneSpring GX for gene expression was migrated to Strand's Avadis platform, and all subsequent versions have been based on Avadis as well.
About Strand Scientific Intelligence, Inc. (Strand)
Strand is a privately held company that has pioneered the practice of scientific intelligence in the health sciences. Leveraging its unmatched interdisciplinary scientific expertise with its decision-enabling technologies, Strand empowers biomedical and research scientists to gain deep insights from raw data. Strand offers products and services in the areas of omics-based technologies, drug discovery, predictive systems modeling and knowledge management. Seven of the top 10 pharmaceutical companies, three of the top six biotechnology companies, and numerous academic institutions across the globe are part of Strand's esteemed customer profile. For more information please visit www.strandsi.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available at www.agilent.com.
# # #
Stuart Matlow, Agilent
Saurabh Narain, Strand